APOBEC3 as a driver of genetic intratumor heterogeneity

Subramanian Venkatesan; Mihaela Angelova; Jirina Bartkova; Samuel F Bakhoum; Jiri Bartek; Nnennaya Kanu; Charles Swanton

doi:10.1080/23723556.2021.2014734

APOBEC3 as a driver of genetic intratumor heterogeneity

Mol Cell Oncol. 2022 Jan 3;10(1):2014734. doi: 10.1080/23723556.2021.2014734. eCollection 2023.

Authors

Subramanian Venkatesan^{1

2}, Mihaela Angelova¹, Jirina Bartkova^{3

4}, Samuel F Bakhoum^{5

6}, Jiri Bartek^{3

4}, Nnennaya Kanu², Charles Swanton^{1

2

7}

Affiliations

¹ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
² Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, University College London, London, UK.
³ Genome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
⁴ Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.
⁵ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁶ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁷ Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.

Abstract

Our recent study revealed that APOBEC3B is upregulated during the preinvasive stages of non-small cell lung cancer and breast cancer. In addition to its role in mediating single nucleotide variants, we propose that APOBEC3 promotes copy number intratumor heterogeneity prior to invasion, providing a substrate for cancer evolution.

Keywords: APOBEC; breast cancer; chromosomal instability; intratumor heterogeneity; non-small cell lung cancer.

Abstract

Grants and funding